BIBLIOGRAFÍA ASMA

BIBLIOGRAFÍA

  1. García-Marcos L, Quirós AB, Hernández GG, Guillén-Grima F, Díaz CG, Urena IC, et al. Stabilization of asthma prevalence among adolescents and increase among schoolchildren (ISAAC phases I and III) in Spain. Allergy. 2004;59:1301-7.
  2. Martínez-Moratalla J, Almar E, Sunyer J, Ramos J, Pereira A, Payo F, et al. Estudio Europeo del Asma. Identificación y tratamiento de individuos con criterios epidemiológicos de asma en adultos jóvenes de cinco áreas españolas. Arch Bronconeumol. 1999;35:223-8.
  3. Martínez-Moragón E, Serra-Batllé J, De Diego A, Palop M, Casan P, Rubio-Terrés C, Pellicer P y por el Grupo de Investigadores del estudio AsmaCost. Coste económico del paciente asmático en España (estudio AsmaCost). Arch Bronconeumol. 2009;45:481–486.
  4. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels R, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study. Am J Respir Crit Care Med 2004;170:836-44.
  5. Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M, Nieminen MM, Kontula E, Laitinen LA. A 10 year asthma programme in Finland: major change for the better. Thorax. 2006;61:663-70.
  6. Olaguibel JM, Quirce S, Juliá B, Fernández C, Fortuna AM, Molina J, Plaza V; MAGIC Study Group. Measurement of asthma control according to Global Initiative for Asthma guidelines: a comparison with the Asthma Control Questionnaire. Respir Res. 2012;13:50.
  7. López Viña A, Cimas JE, Díaz Sánchez C, Coria G, Vegazo O, Picado Valles C. A comparison of primary care physicans and pnermologists in the management of asthma in Spain: ASES study. Respir Med 2003; 97:872-881.
  8. Fueyo A, Ruiz MA, Ancochea J, Guilera M, Badia X; ESCASE Group. Asthma control in Spain. Do season and treatment pattern matter? The ESCASE study. Respir Med. 2007;101:919-24.
  9. Plaza V, Bellido-Casado J, Díaz C, Pérez de Llano L, Sanchis J,  Villasante C, López Viña A. Implicación de los servicios de neumología españoles en la asistencia, docencia e investigación en asma. Resultados de la encuesta ATENEA. Arch Bronconeumol. 2012;48:114-9. 
  10. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4. treatment): INNOVATE. Allergy. 2005 Mar;60(3):309-16.
  11. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et-al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009; 360:973-84.
  12. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, Harris JM, Scheerens H, Wu LC, Su Z, Mosesova S, Eisner MD, Bohen SP, Matthews JG. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088-98.
  13.  Castro M, Rubin AS, Laviolette M, Fiterman J, D Andrade Lima M, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Duhamel DR, McEvoy C, Barbers R, Ten Hacken NH, Wechsler ME, Holmes M, Phillips MJ, Erzurum S, Lunn W, Israel E, Jarjour N, Kraft M, Shargill NS, Quiring J, Berry SM, Cox G; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181:116-24.